drugset / Trial / NCT04352946

HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial

NCT04352946

Phase 3 Unknown 374 enrolled GeoSentinel Foundation
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a double-blinded, randomized placebo-controlled trial to determine if pre-exposure prophylaxis (PrEP) with 400mg hydroxychloroquine (HCQ), taken orally once daily, for health care workers in the hospital reduces symptomatic and asymptomatic COVID-19 disease during the pandemic. 374 health care workers will be randomized at a 1:1 allocation between the intervention and placebo arms and followed for 90 days. The cumulative incidence of COVID-19 infection in the intervention group will be compared to the cumulative incidence of COVID-19 in the placebo group with relative (risk ratio and 95% CI) and absolute measures (risk difference and 95% CI).

Timeline

Start
2020-04-24
Primary completion
2020-06-24
Completion
2020-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 400 mg Oral

Indications